
Cette revue présente une sélection de publications récentes en allergologie professionnelle susceptibles d’avoir un impact sur la pratique clinique. Plusieurs travaux soulignent l’intérêt d’explorer au plus près l’exposition réelle, notamment par des tests réalisés avec les végétaux ou les produits professionnels eux-mêmes. L’identification d’une rhinoconjonctivite professionnelle à la poudre de graines de lin illustre l’émergence de nouveaux allergènes respiratoires, alors qu’en dermatologie de contact, certaines études rappellent que l’étiquetage de produits présentés comme « sans PPD » ou « sans accélérateur » ne garantit pas l’absence de substances sensibilisantes. La description d’un foyer de sensibilisation au dicyclohexylcarbodiimide dans un laboratoire de biotechnologie souligne également l’importance d’une analyse précise des expositions professionnelles. Enfin, les données concernant les plieurs de parachutes rappellent que les atteintes liées au travail incluent aussi des dermatoses irritatives et traumatiques. Ces travaux illustrent une allergologie professionnelle plus attentive à l’exposition réelle, aux allergènes émergents et à la diversité des manifestations cutanées et respiratoires liées au travail.
Les avancées récentes en allergologie médicamenteuse illustrent une évolution vers des approches diagnostiques et thérapeutiques plus personnalisées. De nouveaux biomarqueurs urinaires pourraient faciliter le diagnostic de la maladie respiratoire exacerbée par les AINS, tandis qu’une stratégie séquentielle associant patch test in situ, ROAT et test de provocation améliore l’exploration de l’érythème pigmenté fixe. L’omalizumab apparaît comme un possible adjuvant de certaines désensibilisations médicamenteuses complexes, bien que les données restent limitées. Enfin, l’identification d’une activation persistante des axes CCR8/CCL1 et CXCR3/CXCL10 dans les DRESS prolongés ouvre de nouvelles perspectives thérapeutiques avec les inhibiteurs de JAK. Ces travaux témoignent d’une allergologie médicamenteuse orientée vers un diagnostic plus précis, une réduction des évictions injustifiées et la sécurisation des traitements indispensables.
This review highlights selected publications from 2025 in pediatric allergology with potential implications for clinical practice. In severe pediatric asthma, the expanding use of biologic therapies supports a phenotype- and comorbidity-driven approach, although reliable predictive biomarkers remain unavailable to guide treatment selection. In atopic dermatitis, tapinarof emerges as a promising new non-steroidal topical option for children. In pediatric eosinophilic esophagitis, a milk-only elimination diet appears to provide histological efficacy comparable to a more restrictive diet, with better acceptability. In food allergy, epitope-specific IgE and IgG4 antibodies represent promising biomarkers for predicting the natural history of peanut allergy, although their use remains limited to research settings. Recent data on food protein-induced enterocolitis syndrome highlight the influence of regional complementary feeding practices on triggering foods. Finally, a survey among childcare professionals shows that individualized healthcare plans alone are insufficient to ensure the safety of food-allergic children without regular practical training in anaphylaxis recognition and adrenaline auto-injector use. Overall, these studies illustrate the evolution of pediatric allergology toward more personalized, progressive, and pragmatic care.
This review highlights selected recent publications in food allergy with potential implications for clinical practice. In peanut oral immunotherapy, baseline peanut-specific IgE levels appear to predict remission more accurately than age, whereas the addition of dupilumab provides only a modest improvement in desensitization and does not prevent anaphylaxis. Early and regular introduction of baked egg may promote the development of tolerance in selected high-risk infants, although these findings remain preliminary. In cow's milk allergy, the basophil activation test appears to predict reactions to both baked and fresh milk more accurately and could help identify children who still require an oral food challenge. French real-world data also emphasize the growing role of dupilumab in pediatric eosinophilic esophagitis refractory to conventional treatment. Finally, the identification of a-Gal epitopes in Anisakis suggests a novel potential sensitization pathway, without establishing a clinically overt a-Gal syndrome at this stage. Overall, these studies illustrate the evolution of food allergy care toward more personalized, predictive and targeted strategies.
Occupational allergies caused by exposure to chemical substances represent a major occupational health issue. Identification of the allergenic potential of chemical substances has become imperative, especially since the implementation of the European REACH and CLP regulations. These regulations restrict the use of animal models, accelerating the development of new methodological approaches to replace animal testing over the past two decades. In this context, in vitro biological mechanism-based methods are of substantial relevance. Among these approaches, an in vitro model of dendritic cells known as BMDCs (bone marrow-derived dendritic cells) has been developed. It directly targets the dendritic cell maturation step and enables a quantitative assessment of the allergenic potency of tested substances. This review summarizes the most recent data on the performance of the BMDC model as well as its value relative to other regulatory assays, and highlights its relevance as an alternative model within integrated approaches to predictive toxicology.